Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tarsus Pharmaceuticals (TARS) Receivables (2021 - 2025)

Historic Receivables for Tarsus Pharmaceuticals (TARS) over the last 6 years, with Q3 2025 value amounting to $74.3 million.

  • Tarsus Pharmaceuticals' Receivables rose 14530.1% to $74.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $74.3 million, marking a year-over-year increase of 14530.1%. This contributed to the annual value of $48.1 million for FY2024, which is 17130.52% up from last year.
  • Tarsus Pharmaceuticals' Receivables amounted to $74.3 million in Q3 2025, which was up 14530.1% from $60.2 million recorded in Q2 2025.
  • Tarsus Pharmaceuticals' 5-year Receivables high stood at $74.3 million for Q3 2025, and its period low was $200000.0 during Q4 2021.
  • Its 5-year average for Receivables is $25.1 million, with a median of $20.2 million in 2021.
  • Over the last 5 years, Tarsus Pharmaceuticals' Receivables had its largest YoY gain of 169100.0% in 2022, and its largest YoY loss of 9899.69% in 2022.
  • Over the past 5 years, Tarsus Pharmaceuticals' Receivables (Quarter) stood at $200000.0 in 2021, then soared by 1691.0% to $3.6 million in 2022, then soared by 394.53% to $17.7 million in 2023, then skyrocketed by 171.31% to $48.1 million in 2024, then skyrocketed by 54.68% to $74.3 million in 2025.
  • Its Receivables was $74.3 million in Q3 2025, compared to $60.2 million in Q2 2025 and $64.2 million in Q1 2025.